NCCN Guidelines for Hematopoietic Growth Factors V.1.

2019 – Follow-up on 02/05/2019

Guideline Page Panel Discussion/References Institution Vote

and Request
YES NO ABSTAIN ABSENT

MGF-4 Based on the discussion, the panel consensus was to include tbo-filgrastim 17 1 0 9
Internal request: as a therapeutic MGF option for patient who present with febrile
neutropenia, if they did not receive prophylactic G-CSF and there are risk
Panel comment to consider factors present for an infection-associated complication. This is a category
including tbo-filgrastim as a 2A recommendation.
therapeutic myeloid growth factor
option for patient who present
with febrile neutropenia, if they
did not receive prophylactic G-
CSF and there are risk factors
present for an infection-
associated complication.
MGF-4 Based on the discussion, the panel consensus supported the inclusion of
Internal request: the following growth factors as therapeutic options for patients who present
with acute exposure to myelosuppressive doses of RT:
Institutional review comment to  Filgrastim 18 0 0 9
consider including GM-CSF as a  Filgrastim-sndz 18 0 0 9
therapeutic option for patients  Filgrastim-aafi 18 0 0 9
who present with acute exposure  Tbo-filgrastim 17 1 0 9
to myelosuppressive doses of RT,  Pegfilgrastim 18 0 0 9
based on the FDA approved  Pegfilgrastim-jmdb 18 0 0 9
indication.  Sargramostim 17 1 0 9
MGF-A Based on the discussion, the panel consensus was to include the following 18 0 0 9
Internal request: bone cancer regimens in the list of examples of disease settings and
chemotherapy regimens with a high-risk (>20%) for febrile neutropenia:
Panel comment to consider the  VAI (vincristine, doxorubicin or dactinomycin, ifosfamide)
inclusion of bone cancer  VDC-IE (vincristine, doxorubicin or dactinomycin, and
regimens in the list of examples cyclophosphamide alternating with ifosfamide and etoposide)
of disease settings and  VIDE (vincristine, ifosfamide, doxorubicin or dactinomycin,
chemotherapy regimens with a etoposide)
high/intermediate risk for febrile The panel consensus was to include the following bone cancer regimens in 18 0 0 9
neutropenia. the list of examples of disease settings and chemotherapy regimens with
an intermediate-risk (10-20%) for febrile neutropenia:
 Cisplatin/doxorubicin
 VDC (cyclophosphamide, vincristine, doxorubicin or dactinomycin)